OASM - Oasmia Pharmaceutical AB (publ)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
Currency in SEK. All numbers in thousands
Revenue4/30/20194/30/20184/30/20174/30/2016
Total Revenue11,16612,3267,19523,100
Cost of Revenue4,6184,4034,389-4,776
Gross Profit6,5487,9232,80627,876
Operating Expenses
Research Development----
Selling General and Administrative120,093108,606139,199155,765
Non Recurring----
Others--296-218-218
Total Operating Expenses131,298117,507147,878155,793
Operating Income or Loss-120,132-105,181-140,683-132,693
Income from Continuing Operations
Total Other Income/Expenses Net-18,060-12,832-19,560-8,846
Earnings Before Interest and Taxes-120,132-105,181-140,683-132,693
Interest Expense-18,079-12,311-13,490-8,234
Income Before Tax-138,192-118,013-160,243-141,539
Income Tax Expense32,822---
Minority Interest--6-6-6
Net Income From Continuing Ops-171,014-118,013-160,243-141,539
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-171,020-118,007-160,243-141,539
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-171,020-118,007-160,243-141,539